Grifols | GRFS - Cash And Equivalent

Stock Price
7.66
Daily Change
-0.13 -1.67%
Monthly
-10.93%
Yearly
-1.29%
Q2 Forecast
7.46

Grifols reported EUR979.78M in Cash and Equivalent for its fiscal quarter ending in December of 2024.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Arca Biopharma USD 49.52M 2.58M Mar/2026
aTyr Pharma USD 10.01M 735K Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Immunic USD 186.63M 171.15M Mar/2026
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
TherapeuticsMD 523K 89K Jun/2024